Quick answer: 5-Amino-1MQ, MOTS-c, and NAD+ are studied in metabolic and insulin-signaling research through different pathways. 5-Amino-1MQ is researched as an NNMT inhibitor linked to GLUT4 glucose-transport and NAD+ levels; MOTS-c as an AMPK activator regulating fat oxidation and insulin sensitivity; and NAD+ as the coenzyme supporting insulin-signaling metabolism. Sold for research use only.
What each is studied for
5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme associated with fat storage and metabolic rate in research. The insulin-signaling research angle involves increased GLUT4 transporter expression (studied for moving more glucose into muscle cells) and preserved NAD+ levels (studied for supporting insulin responsiveness). A widely cited UT Southwestern study reported that NNMT inhibition reduced fat mass by ~30% in diet-induced obese mice without altering food intake — an animal research finding, not a human outcome.
MOTS-c is a mitochondrial-derived peptide studied as an activator of AMPK (AMP-activated protein kinase), the metabolic “master switch” that shifts cells toward fat oxidation. MOTS-c research examines metabolic homeostasis, insulin sensitivity, and exercise capacity.
NAD+ is the coenzyme that powers mitochondrial energy production and sirtuin/DNA-repair pathways. In metabolic research, adequate NAD+ is studied for supporting healthy insulin signaling and glucose uptake. (NAD+ also appears in our Longevity pillar — it spans both research areas.)
How the pathways differ
| Compound | Primary studied target | Research angle |
|---|---|---|
| 5-Amino-1MQ | NNMT inhibition | GLUT4 glucose transport; NAD+ preservation; fat-storage research |
| MOTS-c | AMPK activation | Fat oxidation, insulin sensitivity, metabolic homeostasis |
| NAD+ | Coenzyme / sirtuin pathways | Mitochondrial energy and insulin-signaling support |
Why they’re studied together
The most-investigated combination pairs 5-Amino-1MQ (NNMT inhibition) with MOTS-c (AMPK activation) to target fat oxidation and glucose handling through two complementary pathways, often alongside NAD+ to support the underlying coenzyme pool. For incretin-pathway metabolic research (semaglutide, tirzepatide, retatrutide), see our GLP-1 pillar.
Frequently asked questions
What peptides are studied for insulin resistance?
In metabolic research, 5-Amino-1MQ (NNMT inhibitor), MOTS-c (AMPK activator), and NAD+ (coenzyme) are commonly studied for insulin-signaling pathways, alongside the GLP-1 class.
What is the difference between 5-Amino-1MQ and MOTS-c?
5-Amino-1MQ inhibits the NNMT enzyme and is studied for GLUT4 and NAD+ pathways; MOTS-c activates AMPK and is studied for fat oxidation and mitochondrial metabolism. They’re researched as complementary.
What does NNMT inhibition do in research?
Animal studies associate NNMT inhibition with reduced fat mass and preserved NAD+ levels; 5-Amino-1MQ is the most-studied NNMT inhibitor in this space.
Is NAD+ related to insulin sensitivity?
Research suggests adequate NAD+ supports insulin signaling and glucose uptake, which is why it appears in both metabolic and longevity research.
Are these for human use?
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.
Primary-literature anchors
Cite primary sources: Kraus et al. / UT Southwestern NNMT-inhibition obesity research; Lee et al., MOTS-c and AMPK (Cell Metabolism, 2015); NAD+ metabolism and insulin-signaling reviews. Link via PubMed.
For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.